Who are EVENITY's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Romosozumab and Denosumab Cycle Therapy, Romosozumab followed by Denosumab, Evenity, Romosozumab Prefilled Syringe, romosozumab HCP administration with PFS, Placebo to Romosozumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/romosozumab-aqqg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

EVENITY — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EVENITY (ROMOSOZUMAB-AQQG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Bone.

marketed Sclerostin Bone Live · refreshed every 30 min

Target snapshot

EVENITY (ROMOSOZUMAB-AQQG) — AMGEN INC.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EVENITY TARGET	ROMOSOZUMAB-AQQG	AMGEN INC	marketed		Sclerostin
Romosozumab and Denosumab Cycle Therapy	Romosozumab and Denosumab Cycle Therapy	National Taiwan University Hospital	marketed	Bone-forming agent and antiresorptive agent combination therapy	Sclerostin (romosozumab); RANKL (denosumab)
Romosozumab followed by Denosumab	Romosozumab followed by Denosumab	National Taiwan University Hospital	marketed	Sclerostin inhibitor followed by RANKL inhibitor	Sclerostin (romosozumab); RANKL (Denosumab)
Evenity	romosozumab	Amgen	marketed		Sclerostin
Romosozumab Prefilled Syringe	Romosozumab Prefilled Syringe	Karen Klahr Miller, MD	phase 3	Monoclonal antibody	Sclerostin
romosozumab HCP administration with PFS	romosozumab HCP administration with PFS	Amgen	phase 3	Sclerostin inhibitor	Sclerostin
Placebo to Romosozumab	Placebo to Romosozumab	Amgen	phase 3	Sclerostin inhibitor monoclonal antibody	Sclerostin (SOST protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EVENITY — Competitive Intelligence Brief. https://druglandscape.com/ci/romosozumab-aqqg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing